| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
ASTON, Pa.—Prime Synthesis Inc. a develop­er of DNA synthesis support products aimed primarily at the clinical and drug manu­facturing markets, recently announced the formation of a new operating division called 3-Prime LLC, with the intent of providing the same solid support used by these cus­tomers for oligonucleotide production for the research and development market.
 
According to Marc Rothstein, president of 3-Prime, the intent of creating a separate division focused on the research market was to be able to provide the customized service needed to maximize oligo yields and produc­tion at the half dozen or so companies provid­ing these materials to the research markets.
 
"We have seen that there have been a lot of interesting developments and collabora­tions occurring in the research market," he says. "As more and more companies look to perform genomic research, there is an increasing need for oligos to support them and we are in a position to provide value to the companies producing the oligos."
 
In order to ensure that its support prod­ucts are of the highest standard, 3-Prime has turned to one of these manufacturers, Integrated DNA Technologies (IDT), to test and validate its products.
 
According to Trey Martin, COO of IDT: "Researchers working with 3-Prime not only [will] receive effec­tive product for their work, but they will also benefit from IDT's analytical expertise and our expe­rience in high-throughput oligo production."
 
While 3-Prime is providing mate­rials that aid high-volume oligo producers, Rothstein says there is very little fear that any of 3-Prime's potential customers would take that capability in-house.
 
"While nothing we do is pat­ent-protected, we have learned our own trade secrets over the years and have become very efficient at what we do," Rothstein says. "With oligo prices around 50 cents per base, these companies would rather focus their time and effort on further automating their pro­duction and increasing efficiency of their operation than spending a lot of time developing things they can easily get from us."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue